| answer text |
<p>No specific assessment has been made. However, clinical trial results indicate
that the dual oral antiviral nirmatrelvir/ritonavir resulted in a relative risk reduction
of hospitalisation or death by 88% within five days of symptom onset, compared to
placebo in non-hospitalised, high-risk adults with COVID-19. Further results show
that the oral antiviral molnupiravir administered within five days of symptom onset
to high-risk, non-hospitalised patients resulted in a relative risk reduction of 30%
in the composite primary outcome of hospitalisation or death at day 29.</p>
|
 |
